UNSPSC 51292928: Tiracizine hydrochloride

This classification denotes an antiarrhythmic agent with the molecular structure C21H25N3O3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, GB5HGM31RA chemically known as carbamic acid, n-(5-(2-(dimethylamino)acetyl)-10,11-dihydro-5h-dibenz(b,f)azepin-3-yl)-, ethyl ester, hydrochloride (1:1), but more commonly known as tiracizine hydrochloride, which bears US NIH Compound Identifier 107750.

European Medicines Agency schedules Tiracizine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04885MIG. Most nations, for tariff and trade purposes, schedule tiracizine hydrochloride under HS 29339930 and SITC 51577. As of Q4 2014, TIRACIZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)NC1CCC2C(C1)N(C3CCCCC3CC2)C(=O)CN(C)C.CL.

UNSPSC 51292928 Tiracizine hydrochloride is a Commodity code that does not reflect the actual pharmaceutical and health-supply procurement activity appearing in recent state and local solicitations. The three recent opportunities tagged to this code—naloxone and drug deactivation systems procurement, a direct-to-manufacturer prescription program inquiry, and generic multi-source pharmaceutical and OTC product contracting—involve different active pharmaceutical ingredients and supply-chain models, none of which align with tiracizine hydrochloride, a selective histamine H1-receptor antagonist. The mismatch between the code name and the work actually being solicited suggests either miscoding in the state procurement systems or that tiracizine hydrochloride is not a current focus of state and local health-systems purchasing.

The three recent opportunities do signal broader state and local pharmaceutical and health-supply procurement activity across county health departments, state health agencies, and cooperative purchasing alliances. Seminole County, Florida released an IFB on June 30, 2026 (due July 26, 2023—a date discrepancy in the source) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the county community health building, with two-year initial terms and one-year renewal options. Texas Health and Human Services Commission posted an RFI on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with contract effectiveness set for July 1, 2026. Activity spans Florida, Texas, and the Upper Midwest cooperative-purchasing region, though the code itself shows limited concrete procurement relevance for tiracizine hydrochloride specifically.